Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S's market cap is currently ―. The company's EPS TTM is $0.177; its P/E ratio is 12.98; and it has a dividend yield of 6.86%. Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S is scheduled to report earnings on August 9, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	¥ 2.69B	¥ 1.79B	¥ 1.89B	¥ 1.89B	¥ 1.56B
Gross Profit	¥ 1.01B	¥ 725.98M	¥ 810.51M	¥ 744.43M	¥ 506.65M
EBIT	¥ 138.71M	¥ 300.35M	¥ 364.34M	¥ 187.06M	¥ 108.89M
EBITDA	¥ 138.71M	¥ 300.35M	¥ 364.34M	¥ 187.06M	¥ 108.89M
Net Income Common Stockholders	¥ 132.83M	¥ 260.18M	¥ 269.18M	¥ 199.60M	¥ 107.63M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	¥ 2.88B	¥ 2.35B	¥ 2.60B	¥ 2.69B	¥ 2.28B
Total Assets	¥ 10.16B	¥ 9.75B	¥ 9.29B	¥ 9.32B	¥ 9.07B
Total Debt	¥ 257.91M	¥ 112.31M	¥ 51.92M	¥ 30.40M	¥ 33.17M
Net Debt	¥ -2.62B	¥ -2.24B	¥ -2.55B	¥ -2.66B	¥ -2.25B
Total Liabilities	¥ 3.61B	¥ 2.87B	¥ 2.69B	¥ 2.61B	¥ 2.55B
Stockholders Equity	¥ 6.52B	¥ 6.71B	¥ 6.45B	¥ 6.57B	¥ 6.36B
Cash Flow	-
Free Cash Flow	¥ 513.19M	¥ 20.49M	¥ 2.35M	¥ 33.31M	¥ 131.60M
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	¥ -167.76M	¥ -364.87M	¥ 170.55M	¥ 349.80M	¥ -38.25M
Financing Cash Flow	¥ 128.63M	¥ 16.28M	¥ -364.02M	¥ -17.52M	¥ -1.82M

Currency in CNY

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Earnings and Revenue History

Income Statement >

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Debt to Assets

Balance Sheet >

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Cash Flow

Cash Flow >

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing